Georgia Medicaid GLP-1 Coverage (2026): Dual-Level Operational Non-Coverage — Statewide PDL Omission + Peach State Health Plan Explicit 'Drugs Prescribed for Weight Loss' Exclusion

Georgia Medicaid is a dual-level operational non-coverage state for adult GLP-1 weight-loss claims. As of the May 1, 2026 Georgia Medicaid/PeachCare Preferred Drug List, Wegovy and Zepbound are absent from the PDL entirely — zero occurrences across both the class-alphabetical and name-alphabetical PDL extractions. The Statewide PDL maintains a structural “WEIGHT MANAGEMENT AGENTS” class slot that has produced “No changes” through both the November 2025 (effective January 1, 2026) and May 2025 (effective July 1, 2025) P&T Committee review cycles. At the CMO level, Peach State Health Plan — Georgia's largest Georgia Families managed care organization, operated by Centene/Ambetter — publishes an explicit “Exclusions” list in its Member PDL naming “Drugs prescribed for weight loss” as not part of the Peach State PDL and not eligible for the 72-hour emergency-supply override. This CMO-level explicit exclusion language distinguishes Georgia from every other state in this 8-state Medicaid series — it is not found in verbatim form in Texas, California, New York, Florida, Ohio, Illinois, or Pennsylvania CMO documents verified for this series. The operative federal authority is 42 U.S.C. § 1396r-8(d)(2)(A): “Agents when used for anorexia, weight loss, or weight gain.” Unlike Ohio (OAC 5160-9-03), Illinois (89 IAC § 140.441(b)), or New York (18 NYCRR § 505.3(g)(3)), Georgia does not have a state Administrative Code rule explicitly banning Medicaid coverage of weight-loss drugs — a verified absence at Department 350 of the Georgia Administrative Code. Georgia's exclusion is entirely executive and administrative in nature, not regulatory. The only Georgia Medicaid coverage pathway to any obesity pharmacotherapy involves Saxenda (liraglutide 3 mg) and Xenical (orlistat 120 mg) — both listed on the PDL with a pediatric-only PA gate (ages 12–17) that matches the FDA pediatric obesity label. Adults have no coverage pathway for any GLP-1 or weight-management drug for the obesity indication as of the May 1, 2026 PDL. Georgia is not among the 13 state Medicaid programs that KFF (January 16, 2026) identifies as covering GLP-1s for obesity treatment under fee-for-service.

Pattern #8: Dual-level operational non-coverage — where Georgia fits in the 8-state cluster

This article is the eighth installment in our 50-state Medicaid GLP-1 coverage series. The eight states audited to date fall into six structural patterns:

Georgia's structural position is meaningfully distinct from all seven prior patterns. Like Florida, Georgia has no state-level Administrative Code regulation banning weight-loss drug coverage. But unlike Florida's purely silent exclusion (operational by PDL absence only), Georgia adds a second explicit operational layer: Peach State Health Plan's Member PDL names “Drugs prescribed for weight loss” as a categorical exclusion in the printed Exclusions section. This CMO-level explicit language coexists with — and reinforces — the Statewide PDL's operational emptiness for adult AOMs.

The absence of a state Administrative Code rule is also structurally important. In New York, Ohio, and Illinois, a future P&T decision to add Wegovy or Zepbound to the PDL would first require a regulatory amendment — a slower, more politically visible process requiring public notice and comment. In Georgia, a Prime Therapeutics rebate-negotiation outcome at the November P&T review could add either drug to the January 1 PDL without any prior regulatory change. Georgia's exclusion is more administratively flexible — and therefore more reversible — than the doubly- or triply-anchored states.

What the Georgia Statewide PDL covers: the complete GLP-1 table

The Georgia Medicaid/PeachCare Preferred Drug List effective May 1, 2026 is the operative coverage document. The verbatim PDL header (lines 1–9 of the class-alphabetical extraction) reads:

“Georgia Medicaid/PeachCare Preferred Drug List / Effective May 1, 2026 / This Preferred Drug List is subject to change without notice. / This list does not include all drugs covered under the Georgia Medicaid/PeachCare for Kids outpatient pharmacy program. KEY: Preferred / P: medications associated with a lower member copayment; Non-Preferred / NP: medications associated with a higher member copayment; PA: prior authorization required; QLL: quantity or therapy limits apply. The QLL listing and therapy limitation description are located in Part II of the Policies and Procedures for Pharmacy Services Manual located on the web portal, under Provider Manuals.”

The following table reflects verbatim PDL entries for every GLP-1-containing or incretin-modulating agent and every obesity-indicated weight-management drug verified in the May 1, 2026 PDL:

Bottom line: Georgia Medicaid covers GLP-1s exclusively for type 2 diabetes mellitus. There is no adult coverage pathway for any GLP-1 receptor agonist for chronic weight management, MACE reduction, MASH treatment, or obstructive sleep apnea as of the May 1, 2026 PDL. The only pediatric obesity coverage is Saxenda (Non-Preferred, ages 12–17, PA required) and Xenical (Preferred, ages 12–17, PA required).

The “WEIGHT MANAGEMENT AGENTS” class slot: exists on the P&T calendar, operationally empty for adults

One of the most structurally distinctive features of Georgia's PDL architecture is that the Weight Management Agents therapeutic class is not absent from the DCH P&T review framework — it exists as a standing class reviewed every November, with results effective the following January 1. It simply has not produced any adult AOM addition through the two most recent cycles.

From the Georgia Medicaid Class List (278-line PDF verified 2026-05-10), two distinct classes govern GLP-1-related drugs:

• HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS — reviewed in May, effective July 1. This is the class that governs GLP-1 T2D drugs (Mounjaro, Ozempic, Rybelsus, Victoza, Trulicity, exenatide generic). The May 2025 P&T cycle produced no changes to this class.
• WEIGHT MANAGEMENT AGENTS — reviewed in November, effective January 1. This is the class that would govern Wegovy, Zepbound, Saxenda-adult, and other AOMs if they were ever added. The November 2025 P&T cycle produced:

“WEIGHT MANAGEMENT AGENTS No changes”

(Verbatim from the Georgia Therapeutic Class Review Decisions, Effective January 1, 2026, lines 67–68 of the 90-line extracted text.)

The category exists in the schema but contains no covered drugs for adults. This is meaningfully different from a “silent exclusion” state like Florida, where AOMs are not even enumerated in the SMMC plan formularies' class structure. Georgia's “WEIGHT MANAGEMENT AGENTS — No changes” outcome confirms that the class was actively reviewed and no drug was added. It is not evidence of pending coverage — it is confirmation of continued non-coverage.

The Georgia DCH P&T rebate vendor is Prime Therapeutics (per the January 1, 2026 Class Review Decisions document). A future Prime Therapeutics rebate negotiation outcome that produced favorable economics for Wegovy or Zepbound could, in principle, result in a “WEIGHT MANAGEMENT AGENTS — WEGOVY added as Non-Preferred PA Required” outcome at a November P&T cycle — without requiring any parallel state Administrative Code regulatory amendment. This is the key structural difference between Georgia and the NY/OH/IL regulatory-anchor states.

Federal authority: 42 U.S.C. § 1396r-8(d)(2)(A)

The legal foundation for Georgia's non-coverage of GLP-1 weight-loss drugs — as for every non-covering state in this series — is the federal Medicaid optional drug exclusion at 42 U.S.C. § 1396r-8(d)(2). The statute provides verbatim:

“A State may exclude or otherwise restrict coverage of a covered outpatient drug if . . . the drug is contained in the list referred to in paragraph (2).”

Paragraph (2) of the statute enumerates categories of drugs a state may exclude, including verbatim:

“Agents when used for anorexia, weight loss, or weight gain.”

This is a permissive authority — it allows states to exclude weight-loss drugs from Medicaid coverage without violating the federal Medicaid Drug Rebate Program participation requirement. It does not require states to exclude them. Georgia exercises this optional exclusion via the operational mechanisms described in this article: statewide PDL omission of Wegovy and Zepbound, the pediatric-only PA gate for Saxenda and Xenical, and the PSHP CMO explicit weight-loss exclusion language.

The federal authority is identical across all 50 states. What varies state-to-state is the mechanism of operationalization: whether through state Administrative Code regulation (NY's 18 NYCRR § 505.3(g)(3), Ohio's OAC 5160-9-03(B)(1), Illinois's 89 IAC § 140.441(b)), through statewide PDL omission plus CMO-level explicit exclusion (Georgia), through SMMC-plan operational silence (Florida), or through reversed-course re-addition (California's Wegovy MASH April 2026 re-add).

Verified absence: no state Administrative Code rule at Department 350

We verified the Georgia Administrative Code, Department 350 (Department of Medical Assistance — now the Georgia Department of Community Health) directly from the Georgia Secretary of State Rules and Regulations portal on 2026-05-10. Department 350 chapters are:

• Chapter 350-1: Administration
• Chapter 350-2: Procedures for Adoption, Amendment, and Repeal of Rules and for Public Notice of Changes in Methods and Standards for Setting Payment Rates
• Chapter 350-3: Sanctions for Nursing Facilities
• Chapter 350-4: Administrative Review, Hearings and Appeals
• Chapter 350-5: Disclosure of Information on Medicaid Applicants, Recipients and Providers
• Chapter 350-6: Repealed
• Chapter 350-7: Indigent Care Trust Fund — Nursing Home Provider Fee

There is no Georgia Administrative Code rule analogous to:

• New York 18 NYCRR § 505.3(g)(3) (“drugs for weight loss are non-covered”)
• Ohio Administrative Code 5160-9-03(B)(1) (“Drugs for the treatment of obesity” non-covered, with PA explicitly foreclosed as an override route under OAC 5160-9-03(D))
• Illinois 89 IAC § 140.441(b) (“Anorectic drugs or combinations including such drugs” non-covered)

Level 2: The Peach State Health Plan explicit “Drugs prescribed for weight loss” exclusion

The second operational layer of Georgia's non-coverage is the most distinctive feature in the 8-state cluster. Peach State Health Plan (Centene/Ambetter), Georgia's largest Georgia Families managed care organization, publishes an explicit “Exclusions” section in its Member PDL reviewed October 1, 2025, effective for the 2026 plan year. The verbatim text (lines 138–155 of the 10,371-line PSHP PDL extraction) reads:

“Exclusions Below you will find a list of things that are not part of the Peach State PDL. The 72-hour emergency supply policy does not cover these drugs either.     Drugs that are considered experimental     Drug Efficacy Study and Implementation (DESI) drugs     Drugs prescribed for weight loss     Drugs prescribed for infertility     Drugs prescribed for erectile dysfunction     Drugs prescribed for cosmetic purposes or hair growth     Cough and cold preparations     Infusion therapy and supplies     Physician administered drugs, that are not listed in the PDL, Specialty Drug Benefit, or the Physician Administered Drug Prior Authorization List”

This verbatim text establishes three operationally significant points:

1. “Drugs prescribed for weight loss” are categorically not part of the Peach State PDL. This is categorical exclusion language at the CMO Member PDL level — broader than the Statewide PDL's silent omission of specific brand names (Wegovy, Zepbound). A patient prescribed Saxenda for adult obesity — even though Saxenda is on the Statewide PDL for pediatric ages 12–17 — would face this categorical exclusion if they are a PSHP member and the prescription is for the weight-loss indication in an adult.
2. The 72-hour emergency-supply override does NOT extend to weight-loss drugs. Federal Medicaid law guarantees a 72-hour emergency supply for certain denied prescriptions. PSHP explicitly carves out the weight-loss category from this override. This means even the emergency-supply safety net is unavailable for weight-loss-indicated GLP-1 claims at PSHP.
3. The exclusion was reviewed October 1, 2025 and is effective for the full 2026 plan year — it is not a legacy document. PSHP actively maintains this language as current policy.

No other CMO PDL document verified in this 8-state series uses this exact verbatim language. Texas's Superior HealthPlan uses “Non-Covered Benefit” designations in a provider- facing notice. New York's NYRx uses drug-brand-level exclusion naming (“GLP-1 agonists, including but not limited to Ozempic, Wegovy, and Mounjaro are excluded from coverage for weight loss indications”). Florida's SMMC plans use silent PDL-deferral language. Georgia's PSHP is the only CMO in this series to publish a categorical weight-loss exclusion list in the printed Member PDL, explicitly extending the exclusion to the 72-hour emergency-supply provision.

The PSHP PBM for pharmacy claims is Express Scripts, per verbatim from the PSHP PDL Intro (lines 29–32):

“Pharmacy Benefit Manager (PBM) Peach State Health Plan works with Express Scripts to pay for pharmacy claims. Express Scripts is our Pharmacy Benefit Manager (PBM).”

PSHP Member Services PA fax: 1-833-582-2342. Express Scripts Pharmacy Help Desk: 1-833-750-4403.

CareSource Georgia: “All Georgia Medicaid drugs are covered by CareSource”

CareSource Georgia's Medicaid Formulary (Effective 4/1/2026, GA-MED-M-2964344-V.7, DCH Approved 6/21/2024) takes a deferral approach rather than an explicit-exclusion approach. The verbatim CareSource PDL Introduction (lines 6–9 of the 4,358-line extraction) reads:

“INTRODUCTION       This is the 2026 CareSource Medicaid Formulary or Preferred Drug List (PDL).       This list can help providers in picking clinically appropriate and lower priced products.       All Georgia Medicaid drugs are covered by CareSource. This is just a list of preferred drugs.”

This deferral language routes all CareSource formulary questions back to the Georgia Statewide PDL as the operative coverage document. Because Wegovy and Zepbound are absent from the Statewide PDL, CareSource members face the same non-coverage outcome through the deferral mechanism as PSHP members face through the explicit exclusion language.

The CareSource printed PDL does list three GLP-1 antihyperglycemic agents for T2D:

• OZEMPIC — Tier 2, step therapy (ST), quantity limit (QL: 3 mL per 28 days)
• RYBELSUS — Tier 2, ST, QL (1 unit per day), additional restrictions (AR)
• SOLIQUA 100/33 — Tier 2, ST, QL (6 mL per 30 days)

Notably, Trulicity (dulaglutide), Mounjaro (tirzepatide), and Victoza (liraglutide 1.8 mg) — all Preferred or Non-Preferred on the Statewide PDL — are not listed in CareSource's printed formulary. Per CareSource's deferral language, a CareSource member's request for a non-listed drug would route back to the Statewide PDL coverage rules and step therapy for evaluation.

CareSource's printed PDL does not contain an explicit weight-loss exclusion line analogous to PSHP's. The exclusion for CareSource members is operationally inherited from the Statewide PDL's omission of Wegovy and Zepbound, not from a CareSource-published categorical exclusion. CareSource's own PBM is CareSource Pharmacy Management.

Wellpoint Georgia and Humana Healthy Horizons of Georgia: [NOT VERIFIED]

Two additional Georgia Families CMOs — Wellpoint Georgia (formerly Amerigroup/Anthem) and Humana Healthy Horizons of Georgia — joined or expanded the Georgia Families panel in recent years. As of 2026-05-10:

• Wellpoint Georgia: The Wellpoint Georgia Medicaid member-facing pharmacy page returned HTTP 429 (rate-limited) on direct fetch on 2026-05-10. The most recent publicly accessible Wellpoint/Amerigroup Georgia Medicaid PDL is dated February 1, 2018 — predating Wegovy and Zepbound launch and the Wellpoint rebrand — and cannot be cited as current. Wellpoint Georgia uses CarelonRx (a Wellpoint/Anthem affiliate) as its PBM. [NOT VERIFIED — current Wellpoint Georgia Medicaid PDL not publicly retrievable on 2026-05-10.] Wellpoint Georgia members should consult their plan's most recent PDL via member services or the Wellpoint web portal directly.
• Humana Healthy Horizons of Georgia: No current Humana Healthy Horizons of Georgia Medicaid PDL was retrievable in this verification session. [NOT VERIFIED — current Humana Georgia Medicaid PDL not publicly retrievable on 2026-05-10.] Humana members should consult Humana member services for formulary status.

All Georgia Families CMOs are required to align with the Georgia Statewide PDL as the floor. A CMO may choose to be more restrictive but generally not less. The Statewide PDL omission of Wegovy and Zepbound for adults applies structurally across all four CMOs regardless of CMO-specific PDL document verification status.

The most fragmented PBM stack in the series: OptumRx + Express Scripts + CareSource PM + Prime Therapeutics

Georgia's pharmacy benefit management architecture is the most fragmented of any state audited in this 8-state series — with four distinct PBM entities operating simultaneously across the program:

• OptumRx (UnitedHealth Group subsidiary) — the FFS pharmacy benefit administrator for PA intake. OptumRx is the first appearance of a UnitedHealth Group PBM in this series. Prior states used Acentra (TX), Magellan (CA/NY), Gainwell (OH), or in-house PBMS (IL). To initiate a PA for any FFS Georgia Medicaid member, call OptumRx at 1-866-525-5827.
• Express Scripts — PBM for Peach State Health Plan members. PA fax: 1-833-582-2342; Express Scripts Pharmacy Help Desk: 1-833-750-4403.
• CareSource Pharmacy Management — proprietary PBM for CareSource Georgia Medicaid members.
• CarelonRx (Wellpoint/Anthem affiliate) — PBM for Wellpoint Georgia members. [Current PDL NOT VERIFIED as of 2026-05-10.]
• Prime Therapeutics — DCH's PDL rebate negotiation vendor (identified in the January 1, 2026 Therapeutic Class Review Decisions document). Prime manages the drug rebate program for the Statewide PDL, which feeds the CMOs' coverage floors.

The practical implication for Georgia Medicaid patients is that the PA submission process is different depending on which Georgia Families plan you are enrolled in. A FFS patient contacts OptumRx (1-866-525-5827). A PSHP member uses PSHP's PA fax (1-833-582-2342) and routes through Express Scripts. A CareSource member routes through CareSource Pharmacy Management. A Wellpoint member routes through CarelonRx (verify via Wellpoint member services). Unlike Ohio's Gainwell SPBM model (which consolidates all managed-care and FFS pharmacy under one UPDL with one PA process), Georgia has no single statewide pharmacy benefit administrator. This fragmentation means patients and prescribers must identify the correct PBM before initiating any PA, and CMO-specific formulary restrictions may differ at the margins (e.g., PSHP is demonstrably more restrictive on incretin agents than the Statewide PDL).

PA criteria: what's public and what isn't

Georgia DCH does not publish a drug-class-level GLP-1 PA criteria document analogous to Ohio's January 7, 2026 P&T-approved PA Criteria PDF. The Georgia DCH pharmacy PA criteria index at dch.georgia.gov/providers/provider-types/pharmacy/prior-authorization-process-and-criteria lists an “Antidiabetic Agents” link, but as of 2026-05-10, the document URL at dch.georgia.gov/document/document/antidiabetic-agents-0/download returned a 404 HTML page on direct curl. The N–Z PA criteria index page lists no GLP-1, incretin, or Weight Management criteria document.

The PA criteria document that is publicly available — the Georgia Medicaid FFS Hypoglycemics, Insulin and Related Agents PA Summary (Revised 07/03/2023) — covers insulins only. It does not govern GLP-1 receptor agonist PA decisions. The PA Summary provides this navigation guidance verbatim:

“For online access to the PA process, please go to www.dch.georgia.gov/prior-authorization-process-and-criteria and click on Prior Authorization (PA) Request Process Guide.”

And for the FFS PA intake:

“EXCEPTIONS: • Exceptions to these conditions of coverage are considered through the prior authorization process. • The Prior Authorization process may be initiated by calling OptumRx at 1-866-525-5827.”

Because there is no publicly available GLP-1 PA criteria document for the weight-management indication (and because Wegovy and Zepbound are not on the PDL at all), there is no documented public pathway through which a Georgia Medicaid member could obtain a PA approval for Wegovy or Zepbound for adult chronic weight management. The absence of published PA criteria is not a loophole — it reflects the absence of a covered benefit to apply PA criteria to.

The pediatric obesity pathway: Saxenda and Xenical for ages 12–17

Georgia Medicaid's pediatric obesity pathway is one of the more structurally distinctive features in this 8-state series. Most states that exclude adult AOM coverage also omit pediatric obesity drugs. Georgia instead explicitly includes a pediatric-only PA gate, matching the FDA pediatric obesity label expansions for both Saxenda and Xenical.

From the May 1, 2026 PDL (verified by line-level extraction):

• SAXENDA (liraglutide 3 mg) — listed in the ANTIHYPERLIPIDEMIC AGENTS section as Non-Preferred with “PA (12 yrs-17 yrs)”. PA is available only for the pediatric obesity indication (ages 12–17). Adult Saxenda PA requests fall outside the PDL-flagged eligible age range and would be denied. Saxenda's FDA-approval for pediatric chronic weight management (ages 12–17 with initial BMI ≥ 95th percentile for age and sex) was expanded in December 2020.
• XENICAL (orlistat 120 mg) — listed as “Preferred (covered 12–17 yrs old)” with “PA (12 yrs-17 yrs)”. Xenical has FDA approval for adolescent obesity as young as age 12. Like Saxenda, the adult indication is not covered by Georgia Medicaid.

A note on Imcivree (setmelanotide) for genetic obesity: CareSource Georgia has a pharmacy policy document for Imcivree (policy effective 4/1/2022) that covers the rare monogenic/syndromic genetic obesity indication (POMC, LEPR, MC4R deficiency, Bardet-Biedl syndrome) applicable below age 12 in some cases. The specific contents of CareSource's Imcivree PA criteria were not extracted in this verification session and are marked [NOT VERIFIED] — the article notes the policy exists but does not state criteria. Genetic obesity is a separate and rare pathway from general pediatric obesity.

T2D vs weight-loss: the most important distinction for Georgia Medicaid patients

The single most consequential piece of information for a Georgia Medicaid patient who has been prescribed a GLP-1 is the distinction between the type 2 diabetes indication and the weight-management indication. These are separate FDA-approved indications, separate PDL classifications, and separate PA pathways.

• GLP-1s for T2D — covered with PA: Mounjaro (Non-Preferred, PA/QLL), Ozempic (Non-Preferred, PA/QLL), Rybelsus (Non-Preferred, PA/QLL), Soliqua (Non-Preferred, PA/QLL), Trulicity (Non-Preferred, PA/QLL), Xultophy (Non-Preferred, PA/QLL), and exenatide generic (Preferred, QLL), and Victoza (Preferred, QLL). A patient with a documented T2D diagnosis (A1C ≥ 6.5% or other ADA criteria per DailyMed label) can pursue PA for these drugs. Mounjaro and Ozempic brand-name, in particular, have both T2D and weight-management FDA indications — but Georgia Medicaid covers them only under the T2D indication. A claim submitted with a weight-management ICD-10 code (e.g., E66.09, E66.01) will deny; a claim submitted with a T2D ICD-10 code (e.g., E11.9) with appropriate PA documentation may be approved.
• GLP-1s for weight management in adults — NOT covered: Wegovy (semaglutide 2.4 mg, the weight-management dose) and Zepbound (tirzepatide for weight management) are not on the PDL at all. A claim for Wegovy or Zepbound for any adult patient will deny at point of sale.
• Georgia has no MACE or MASH carve-back-in: Unlike Ohio (which opened a Wegovy MACE and MASH PA pathway effective January 7, 2026) and New York (which has a narrow Wegovy MACE DUR pathway with BMI ≥ 40 threshold), Georgia Medicaid has published no Wegovy MACE or MASH coverage pathway as of the May 1, 2026 PDL. Wegovy is not on the PDL for any indication. The verified absence covers MACE, MASH, and obstructive sleep apnea.

Georgia Pathways to Coverage 1115 waiver: same PDL, additional eligibility layer

Georgia is the only state in this 8-state series operating an active Medicaid work-requirement waiver. Georgia Pathways to Coverage — the country's only currently operational Medicaid work-requirement program — was extended by CMS through December 2026 (CMS extension approval September 23, 2025). Pathways covers adults aged 19–64 with household incomes up to 95% of the Federal Poverty Level plus a 5% income disregard who meet the work requirement (≥ 80 hours/month of qualifying activities).

The key pharmacy-benefit clause in the Pathways terms is: Pathways enrollees “are eligible to receive the same state plan benefits as other Medicaid groups, with the exception of nonemergency medical transportation (NEMT).” This means Pathways enrollees receive the same Georgia Statewide PDL as traditional Medicaid enrollees. The work-requirement structure is aneligibility filter, not a coverage carve-out. A Pathways enrollee who meets work-requirement criteria has the same PDL as a traditional Georgia Medicaid enrollee — which means the same absence of Wegovy and Zepbound from the adult AOM class, and the same Saxenda/Xenical pediatric-only PA gate.

The Pathways work requirement does not affect the legal analysis in this article. The GLP-1 weight-loss exclusion applies to all Georgia Medicaid benefit groups governed by the Statewide PDL.

KFF classification: not among the 13 covering states

KFF's January 16, 2026 tracker (“Medicaid Coverage of and Spending on GLP-1s”) reports verbatim:

“13 state Medicaid programs covered GLP-1s for obesity treatment under fee-for-service as of January 2026.”

And:

“four states eliminated coverage (California, New Hampshire, Pennsylvania, and South Carolina) and . . . North Carolina temporarily eliminated then reinstated coverage.”

Georgia is not among the 13 state Medicaid programs KFF identifies as covering GLP-1s for obesity treatment. This is consistent with the verified May 1, 2026 PDL omission of Wegovy and Zepbound for adults.

Important hedge: the KFF public-facing article does not enumerate the 13 covered states by name. This article does not claim “Georgia is one of 37 non-covering states” — the precise count depends on how partial-coverage states (those with MACE-only or MASH-only pathways, like Ohio and New York) are counted. The operative finding is the PDL omission verified directly from primary sources, not a state-count inference from the KFF aggregate number.

No active Georgia legislation: [VERIFIED ABSENCE] as of March 17, 2026

Georgia's legislative posture on GLP-1 Medicaid coverage is passive — neither expanding nor explicitly restricting AOM coverage through legislation. Georgians for a Healthy Future (GHF), the principal health-policy advocacy organization in Georgia, publishes weekly legislative tracking updates throughout the Georgia General Assembly session. Through Week 9 of the 2026 session (March 17, 2026 — the bill-crossover deadline week), GHF's legislative update contains no reference to GLP-1, obesity drugs, anti-obesity medications, Wegovy, Zepbound, or Medicaid weight-management drug coverage.

This is meaningfully different from:

• California, where the AB 575 and SB 535 legislative debate and the CalAIM/budget process drove the January 2026 reversal and the April 2026 MASH re-add.
• New York, where three pending 2025–2026 session bills (A09360, S5798, A2715/S3104) would mandate NYRx coverage of FDA-approved GLP-1s for chronic weight management.
• Louisiana, where SB 433 was actively pending at the time of this article's publication to add Medicaid AOM coverage.

Georgia's legislature has not introduced, advanced, or enacted any bill that would mandate Georgia Medicaid coverage of GLP-1 medications for weight loss as of this article's publication date. This article does NOT speculate about whether Georgia will act in future sessions. The empirical record through Week 9 of the 2026 session is silence.

Georgia State Health Benefit Plan (SHBP): separate program, separate formulary

Some external sources note that Georgia covers Wegovy for state employees under SHBP. To be explicit: this article addresses Georgia Medicaid only. Any SHBP GLP-1 coverage that may apply to state employees is a separate and operationally distinct benefit. SHBP coverage of a GLP-1 for a state employee has zero bearing on Georgia Medicaid coverage for a Medicaid enrollee.

Who is excluded from GLP-1 weight-loss coverage under Georgia Medicaid

As of the May 1, 2026 Georgia Medicaid Statewide PDL:

1. Adults seeking GLP-1s for chronic weight management — excluded by PDL omission of Wegovy and Zepbound and by Saxenda's pediatric-only PA gate. No coverage pathway as of the May 1, 2026 PDL revision.
2. Adults seeking Wegovy for MACE or MASH — excluded by Wegovy not being listed on the PDL under any indication. Georgia has no Wegovy MACE or MASH carve-back-in pathway, unlike Ohio (Jan 7, 2026 P&T) or New York (DUR pathway).
3. Adults seeking Zepbound for OSA — excluded. Zepbound is not listed on the PDL for any indication.
4. Adults seeking older AOMs (Qsymia, Contrave, phentermine) — excluded by PDL omission. No coverage pathway for any standalone obesity medication for adults.
5. PSHP members seeking any weight-loss drug — additionally excluded by the explicit PSHP Member PDL categorical exclusion, including from the 72-hour emergency-supply override.
6. Pediatric patients (ages 12–17) seeking Saxenda or Xenical — covered subject to PA (PDL flag “PA (12 yrs-17 yrs)”). This is a narrow carve-in for a specific age band, not evidence of adult coverage.
7. Adults with T2D seeking GLP-1 for T2D — covered subject to PA. Seven T2D-indicated GLP-1 and combination drugs on the PDL are accessible with documented T2D diagnosis. The preferred agent is exenatide generic.
8. CHIP / PeachCare for Kids enrollees (above-Medicaid-income children) — PeachCare for Kids is administered jointly with the Georgia Medicaid PDL per the PDL header (“Georgia Medicaid/PeachCare Preferred Drug List”). The same PDL entries apply.
9. Dual-eligibles (Medicare + Georgia Medicaid) — dual-eligible members with Medicare Part D coverage have separate coverage rules through the Medicare Part D formulary. Medicare Part D plans that include Wegovy under the cardiovascular indication (effective January 1, 2026 under the CMS Medicare GLP-1 policy for the SELECT-trial indication) may provide a coverage pathway for dual-eligible members that does not depend on Georgia Medicaid PDL status. Verify directly with the Medicare Part D plan.

Appeal pathway: DCH Administrative Hearings + OSAH + Superior Court

Georgia Medicaid applicants and recipients have the right to an impartial fair hearing per the Georgia Administrative Procedure Act (O.C.G.A. § 50-13) and federal Medicaid regulations.

Step 1: CMO internal appeal

For Georgia Families managed-care members (PSHP, CareSource, Wellpoint, Humana), the first step after a PA denial is a CMO internal appeal. Each CMO's Member Handbook specifies the appeal timeline — typically 60 days from the denial notice for non-urgent standard appeals and 72 hours for expedited urgent appeals. Contact the CMO Member Services line on your ID card.

Step 2: State Fair Hearing through OSAH

After exhausting the CMO internal appeal, or for FFS denials, request a State Fair Hearing through the Office of State Administrative Hearings (OSAH). The fair-hearing request must be filed within 30 days from the date of the denial notice. OSAH schedules hearings consistent with the Georgia Administrative Procedure Act and OSAH's Administrative Rules of Procedure. Hearings may be conducted in the county at the DFCS or other government office, at the OSAH office in Atlanta, or by telephone.

Step 3: Judicial review — Superior Court

Every OSAH Administrative Law Judge (ALJ) decision is a final decision that may be appealed only by filing a petition for judicial review in the Fulton County Superior Court OR in the Superior Court in the county of residence of the petitioner.

What to do if you are a Georgia Medicaid member who needs a GLP-1 for weight loss

As of the May 1, 2026 PDL, Georgia Medicaid members who need a GLP-1 for weight management have four realistic pathways:

1. T2D coverage pathway (if you have documented T2D): If you have a documented type 2 diabetes diagnosis (A1C ≥ 6.5% or other ADA-standard criteria), you may qualify for PA approval for Mounjaro (tirzepatide T2D indication), Ozempic (semaglutide T2D indication), or Trulicity (dulaglutide) on the Non-Preferred tier with PA. Exenatide generic (Preferred, QLL) is available without a separate PA in many cases. Your prescriber must submit the PA with T2D diagnosis documentation — not a weight-management ICD-10 code. These GLP-1s produce weight loss as a secondary effect of T2D management even though the indication on the claim is T2D, not obesity. Contact OptumRx (FFS: 1-866-525-5827) or your CMO-specific PBM to initiate the PA.
2. Pediatric pathway (if the patient is ages 12–17 with obesity): Saxenda (NP, ages 12–17, PA required) and Xenical (P, ages 12–17, PA required) are the only direct anti-obesity pharmacotherapy options with a published PDL pathway. No BMI thresholds or comorbidity criteria are publicly documented for the Georgia FFS pathway — contact OptumRx or your CMO PBM for current PA criteria before submission.
3. Cash-pay direct-to-consumer programs: Foundayo (oral orforglipron from Eli Lilly, FDA-approved April 1, 2026) and Wegovy direct programs are cash-pay options that do not involve Georgia Medicaid billing at all. LillyDirect offers Zepbound vials at $299–$449/month depending on dose tier. NovoCare's Wegovy access program offers $299/month for commercially insured patients; Medicaid patients are not eligible for commercial co-pay programs, but income-based patient assistance may be available. We do not endorse cash-pay as a long-term solution — mention it as a realistic option, not a recommendation.
4. Clinical trial enrollment: Active GLP-1 clinical trials enrolling adult patients with obesity may provide access to investigational or FDA-approved GLP-1s at no cost. Search clinicaltrials.gov for active trials in Georgia. Discuss eligibility criteria with your prescriber.

Related research

• Florida Medicaid GLP-1 coverage (2026): the silent exclusion — the closest structural analogue to Georgia in this 8-state series. Both states rely on operational mechanisms rather than state Administrative Code regulations, and both lack a MACE or MASH carve-back-in pathway. The key structural difference: Florida's exclusion is purely silent (PDL operational absence only), while Georgia layers an explicit CMO Member PDL exclusion (“Drugs prescribed for weight loss” with verbatim 72-hour emergency-supply carve-out) on top of the Statewide PDL omission — making Georgia's exclusion dual-level operational vs Florida's single-level silent model.
• Texas Medicaid GLP-1 coverage + STAR+PLUS PA pathway (2026) — companion 50-state series article. Texas uses an explicit “Non-Covered Benefit” designation in the Superior HealthPlan June 2023 provider notice (a verbatim CMO- level exclusion anchored on federal authority and the TX Administrative Code Title 1 § 354.1832). Georgia's PSHP “Drugs prescribed for weight loss” CMO exclusion is the closest structural parallel to the Texas CMO explicit non-coverage language — both anchor on federal authority, both use CMO member-facing language to reinforce the state PDL exclusion. The key difference: TX also has a state Administrative Code hook; GA's CMO explicit language exists alongside a verified absence of any state regulation.
• Ohio Medicaid GLP-1 coverage (2026): triple-anchored exclusion + the January 2026 Wegovy MACE/MASH carve-back-in — companion 50-state series article. Ohio represents the strongest-exclusion model with a state regulation plus a Gainwell SPBM real-time claim gate — and the most advanced carve-back-in in the series (Wegovy MACE + MASH PA pathway effective January 7, 2026, BMI ≥ 27, no T2D required). Georgia has no equivalent carve-back-in pathway and no state regulation. The Gainwell SPBM model (single PBM for all Medicaid) is structurally the opposite of Georgia's fragmented four-PBM stack.
• New York Medicaid (NYRx) GLP-1 coverage + Wegovy MACE pathway (2026) — companion 50-state series article. New York has the strongest-evidenced exclusion in the series (triple-anchored: federal statute + 18 NYCRR § 505.3(g)(3) state regulation + explicit NYRx brand-name contractor documentation) plus a narrow Wegovy MACE pathway (BMI ≥ 40, stricter-than-FDA-label, lifetime cap of 2 attempts). Georgia has no state regulation and no MACE pathway — a structurally weaker explicit exclusion but operationally equivalent non-coverage for adults.
• Illinois Medicaid GLP-1 coverage (2026): the strictest exclusion — doubly-anchored on 89 IAC § 140.441(b) + HFS PDL absence — companion 50-state series article. Illinois is the strictest-exclusion state in the series with the oldest state regulation (last amended May 2014, five months before Saxenda's December 2014 FDA approval). Unlike Georgia, Illinois also has a state-employee coverage asymmetry (5 ILCS 375/6.11c mandates injectable GLP-1 coverage for state employees with obesity effective July 1, 2024). Georgia's SHBP vs Medicaid distinction parallels the Illinois state-employee / Medicaid asymmetry.
• GLP-1 insurance dropped coverage appeal playbook — the four-phase appeal logic (internal CMO appeal, OSAH State Fair Hearing, cash-pay bridge, switch-brand) applicable to Georgia Medicaid fair-hearing requests at OSAH. Note the hedge: a Wegovy/Zepbound denial for the adult weight-management indication cannot be reversed by a State Fair Hearing; the hearing officer applies the PDL as written.
• GLP-1 insurance coverage across Medicare, Medicaid, and commercial — the federal-state coverage framework, KFF state tracker, and how Wegovy/Zepbound/Foundayo actually flow through Medicare Part D and state Medicaid programs. Dual-eligible Georgia Medicaid members with Medicare Part D coverage may access the CMS Medicare GLP-1 cardiovascular-indication benefit beginning January 1, 2026 without relying on Georgia Medicaid PDL status.
• Aetna GLP-1 prior-authorization guide — verbatim Aetna 4774-C/6947-C/1227-C commercial coverage policies. Note that Aetna Better Health of Georgia (a Georgia Families CMO that was not verified in this article's scope) operates under Georgia Medicaid PDL rules — not under Aetna commercial policies. This article is the primary reference for Aetna commercial plan members; Georgia Medicaid members should use the Georgia Medicaid PDL analysis above.
• Wegovy alternatives 2026 — for Georgia Medicaid members who do not qualify for T2D-indicated GLP-1 PA and are evaluating cash-pay Zepbound, Foundayo, Saxenda, and the broader weight-management landscape.